Bacterial Infections — A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
Citation(s)
A Phase III Randomized, Partially Double-Blind, Active-Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 6 Months Concomitantly With Prevnar 13™ and RotaTeq ™